Recent 8-K filings for SI
Highest-materiality recent filing
Shoulder Innovations reports Q4 revenue $14.4M (+65%), FY2025 revenue $47.3M (+50%), guides 2026 to $62-65M
- Net revenue Q4 $14.4M (+65% YoY); FY2025 $47.3M (+50% YoY). Gross margin 76.7% Q4, 76.5% FY.
- Net loss Q4 $7.8M, FY $40.4M; Adjusted EBITDA loss Q4 $7.0M, FY $36.1M.
-
Shoulder Innovations Q1 revenue up 65% to $16.7M, raises FY2026 guidance to $65-68M
Net revenue $16.7M (+65% YoY); implant systems sold 2,184 (+51%); gross margin 77.7%.
-
Shoulder Innovations launches InSet I-135RFX Humeral Stem with expanded fracture indications
Full commercial launch of InSet I-135RFX Humeral Stem after limited market release and FDA 510(k) clearance for fracture indications.
-
Shoulder Innovations signs 10-year lease for new 15,200 sq ft HQ in Byron Center, MI
Lease with Ventura Office Park Lot #8, LLC for a new building with office/warehouse space.
-
Net revenue Q4 $14.4M (+65% YoY); FY2025 $47.3M (+50% YoY). Gross margin 76.7% Q4, 76.5% FY.
-
Shoulder Innovations Q3 revenue up 58% to $11.8M; raises FY25 guidance to $45-46M
Revenue $11.8M (+58% YoY); net loss $8.7M vs $4.1M loss in Q3 2024.
-
Shoulder Innovations Q2 revenue $11M (+33% YoY); FY2025 guidance $42-44M
Q2 net revenue $11.0M, up 33% YoY; gross margin 76.2% (vs 76.9%).
-
Shoulder Innovations adopts post-IPO charter with classified board, exclusive forum clauses
Authorized common stock set at 730M shares; 20M shares of undesignated preferred stock authorized.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event earnings